Can a simple pill save Insulin-Making cells in type 1 diabetes?

NCT ID NCT05594563

Ongoing Disease control Sponsor: Emily K. Sims Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether the drug DFMO can protect the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. About 81 participants will take either DFMO or a placebo twice daily for six months. Researchers will measure insulin production and check for side effects over a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Difluoromethylornithine (DFMO)
What this could lead to: If it works, this could point toward a way to help people with new-onset type 1 diabetes keep making some of their own insulin for longer.
What could go wrong: This is a small, early-phase trial with only 81 people. The drug may not work better than placebo, and side effects like hearing changes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Barbara Davis Center

Aurora, Colorado, 80045, United States
Children's Mercy Hospital

Kansas City, Kansas, 64108, United States
IU Health Riley Hospital for Children

Indianapolis, Indiana, 46202, United States
MHealth Fairview Masonic Children's Hospital and Specialty Clinics

Minneapolis, Minnesota, 55454, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.